BridgeBio Pharma, Inc. Announces Pricing of Secondary Offering of Common Stock

PALO ALTO, Calif. – February 12, 2021 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of a secondary public offering of 3,000,000 shares of its common stock at a price per share of $62.50 by selling stockholder KKR Genetic Disorder L.P. The selling stockholder has also granted the […]